Andere talen Solid Biosciences Inc.

Aandelen

SLDB

US83422E2046

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,26 ^USD	-7,31%		-13,13%	+50,81%

01/04	SGT-003 van Solid Biosciences ontvangt het label zeldzame pediatrische ziekte van de Amerikaanse FDA	MT
01/04	Solid Biosciences Inc. Ontvangt aanwijzing als zeldzame pediatrische ziekte van de FDA voor SGT-003, kandidaat-gentherapie voor Duchenne spierdystrofie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	01/04
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	01/04
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	27/03
North American Morning Briefing : Inflation -2-	15/03
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	13/03
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	07/03
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	07/03
Solid Biosciences to Participate at Upcoming Investor Conferences	06/03
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	16/01
Solid Biosciences Gets Orphan Drug Designation for SGT-003	16/01
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	16/01
Top Midday Gainers	09/01
Solid Biosciences Shares Surge After Revealing $109 Million Private Placement	09/01
Solid Biosciences Announces $109 Million Private Placement	08/01
Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors	08/01
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Solid Biosciences Inc.

Aandelen

SLDB

US83422E2046

Andere talen

Filters